Biogen's 'shockingly broad' Aduhelm label—and $56K price—set up a $10B launch, analysts say

Biogen didn't just win the most closely watched FDA green light of the year. Its newly minted Alzheimer's drug, Aduhelm, snared an approval that covers all Alzheimer's patients, not just a select group of them, meaning millions could be eligible.

And it set an aggressive price tag, in the words of one analyst, that's several times higher than market watchers had predicted—roughly $56,000 for the average patient.